Global Panic Disorders
Global Panic Disorders

Panic Disorders Comprehensive Study by Type (Anxiety Disorders, Generalized Anxiety Disorder, Obsessive-Compulsive Disorder), Application (Hospitals, Specialty Clinics, Home Care, Others), Drug Type (Anti-Depressants, Benzodiazepines), Sales Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Players and Region - Global Market Outlook to 2026

Panic Disorders Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 247 Pages 198 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Panic Disorders Market Scope?
Panic disorder is an intensive surge of worry and anxiety. Itís continual, disabling, and characterized by its unexpectedness and debilitating immobilization intensity. Symptoms embody trembling, nausea, shortness of breath, heart palpitations, numbness, and others. Panic disorders could last for 5-10 minutes; however, it will linger for hours. If it is left untreated, panic disorders reach phobia.

The Panic Disorders market study is being classified by Type (Anxiety Disorders, Generalized Anxiety Disorder and Obsessive-Compulsive Disorder), by Application (Hospitals, Specialty Clinics, Home Care and Others) and major geographies with country level break-up.

The global market for Panic Disorder is fragmented by the global players owing to the growing mental stress and disorders population. The players should focus on innovating the eligible tests and foolproof diagnosis with the right medicinal treatments to grab market share. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Panic Disorders market throughout the predicted period.

Teva Pharmaceutical Inc. (United States), Sun Pharmaceuticals (India), Mylan (United States), Astrazeneca (United Kingdom), Abbott Laboratories (United States), Noven Pharmaceuticals, Inc. (United States), Recordati Rare Diseases (United States), F. Hoffmann-La Roche (Switzerland), Eli Lilly and Company (United States) and Bristol-Myers Squibb (United States) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Panic Disorders market by Type, Application and Region.

On the basis of geography, the market of Panic Disorders has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their development strategies
In 2019, Generic drug giant Mylan NV was acquired by Upjohn, Pfizer Inc.ís medicines business. This merger will combine the strength of both companies to create a specialty generic drug company.



Influencing Market Trend
  • Development of New Product and R&D Activities

Market Drivers
  • Rising Prevalence of Panic Disorders

Opportunities
  • R&D to Develop a Safe and Effective Treatment for Panic Disorders

Restraints
  • Lack of Awareness and Effective Evidence-Based Medicinal Treatment

Challenges
  • Poor Diagnosis Rate Due To Lack of Proper Diagnostic Test


Key Target Audience
Panic Disorder Medicine Manufacturer, Raw Material manufacturer, Healthcare Firms, End-User Industry and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Frequently Asked Questions (FAQ):

1. At what growth rate would the Panic Disorders market expands?
The Global Panic Disorders market is expected to see a growth of % during projected year 2020 to 2026.

2. Who are the prominent players of the Global Panic Disorders market?
The prominent players of Global Panic Disorders market are Teva Pharmaceutical Inc. (United States), Sun Pharmaceuticals (India), Mylan (United States), Astrazeneca (United Kingdom), Abbott Laboratories (United States), Noven Pharmaceuticals, Inc. (United States), Recordati Rare Diseases (United States), F. Hoffmann-La Roche (Switzerland), Eli Lilly and Company (United States) and Bristol-Myers Squibb (United States), to name a few.

3. What are the top priorities to focus for Panic Disorders marketís growth?
In this highly competitive & fast evolving Panic Disorders industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.
Report Objectives / Segmentation Covered
By Type
  • Anxiety Disorders
  • Generalized Anxiety Disorder
  • Obsessive-Compulsive Disorder
By Application
  • Hospitals
  • Specialty Clinics
  • Home Care
  • Others
By Drug Type
  • Anti-Depressants
  • Benzodiazepines

By Sales Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Panic Disorders
    • 3.3. Market Challenges
      • 3.3.1. Poor Diagnosis Rate Due To Lack of Proper Diagnostic Test
    • 3.4. Market Trends
      • 3.4.1. Development of New Product and R&D Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Panic Disorders, by Type, Application, Drug Type, Sales Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Panic Disorders (Value)
      • 5.2.1. Global Panic Disorders by: Type (Value)
        • 5.2.1.1. Anxiety Disorders
        • 5.2.1.2. Generalized Anxiety Disorder
        • 5.2.1.3. Obsessive-Compulsive Disorder
      • 5.2.2. Global Panic Disorders by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Specialty Clinics
        • 5.2.2.3. Home Care
        • 5.2.2.4. Others
      • 5.2.3. Global Panic Disorders by: Drug Type (Value)
        • 5.2.3.1. Anti-Depressants
        • 5.2.3.2. Benzodiazepines
      • 5.2.4. Global Panic Disorders by: Sales Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Retail Pharmacy
        • 5.2.4.3. Online Pharmacy
      • 5.2.5. Global Panic Disorders Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Panic Disorders: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceutical Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sun Pharmaceuticals (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Astrazeneca (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Noven Pharmaceuticals, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Recordati Rare Diseases (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. F. Hoffmann-La Roche (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol-Myers Squibb (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Panic Disorders Sale, by Type, Application, Drug Type, Sales Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Panic Disorders (Value)
      • 7.2.1. Global Panic Disorders by: Type (Value)
        • 7.2.1.1. Anxiety Disorders
        • 7.2.1.2. Generalized Anxiety Disorder
        • 7.2.1.3. Obsessive-Compulsive Disorder
      • 7.2.2. Global Panic Disorders by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Specialty Clinics
        • 7.2.2.3. Home Care
        • 7.2.2.4. Others
      • 7.2.3. Global Panic Disorders by: Drug Type (Value)
        • 7.2.3.1. Anti-Depressants
        • 7.2.3.2. Benzodiazepines
      • 7.2.4. Global Panic Disorders by: Sales Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Retail Pharmacy
        • 7.2.4.3. Online Pharmacy
      • 7.2.5. Global Panic Disorders Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Panic Disorders: by Type(USD Million)
  • Table 2. Panic Disorders Anxiety Disorders , by Region USD Million (2015-2020)
  • Table 3. Panic Disorders Generalized Anxiety Disorder , by Region USD Million (2015-2020)
  • Table 4. Panic Disorders Obsessive-Compulsive Disorder , by Region USD Million (2015-2020)
  • Table 5. Panic Disorders: by Application(USD Million)
  • Table 6. Panic Disorders Hospitals , by Region USD Million (2015-2020)
  • Table 7. Panic Disorders Specialty Clinics , by Region USD Million (2015-2020)
  • Table 8. Panic Disorders Home Care , by Region USD Million (2015-2020)
  • Table 9. Panic Disorders Others , by Region USD Million (2015-2020)
  • Table 10. Panic Disorders: by Drug Type(USD Million)
  • Table 11. Panic Disorders Anti-Depressants , by Region USD Million (2015-2020)
  • Table 12. Panic Disorders Benzodiazepines , by Region USD Million (2015-2020)
  • Table 13. Panic Disorders: by Sales Channel(USD Million)
  • Table 14. Panic Disorders Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 15. Panic Disorders Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 16. Panic Disorders Online Pharmacy , by Region USD Million (2015-2020)
  • Table 17. South America Panic Disorders, by Country USD Million (2015-2020)
  • Table 18. South America Panic Disorders, by Type USD Million (2015-2020)
  • Table 19. South America Panic Disorders, by Application USD Million (2015-2020)
  • Table 20. South America Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 21. South America Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 22. Brazil Panic Disorders, by Type USD Million (2015-2020)
  • Table 23. Brazil Panic Disorders, by Application USD Million (2015-2020)
  • Table 24. Brazil Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 25. Brazil Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 26. Argentina Panic Disorders, by Type USD Million (2015-2020)
  • Table 27. Argentina Panic Disorders, by Application USD Million (2015-2020)
  • Table 28. Argentina Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 29. Argentina Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 30. Rest of South America Panic Disorders, by Type USD Million (2015-2020)
  • Table 31. Rest of South America Panic Disorders, by Application USD Million (2015-2020)
  • Table 32. Rest of South America Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 33. Rest of South America Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 34. Asia Pacific Panic Disorders, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Panic Disorders, by Type USD Million (2015-2020)
  • Table 36. Asia Pacific Panic Disorders, by Application USD Million (2015-2020)
  • Table 37. Asia Pacific Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 38. Asia Pacific Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 39. China Panic Disorders, by Type USD Million (2015-2020)
  • Table 40. China Panic Disorders, by Application USD Million (2015-2020)
  • Table 41. China Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 42. China Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 43. Japan Panic Disorders, by Type USD Million (2015-2020)
  • Table 44. Japan Panic Disorders, by Application USD Million (2015-2020)
  • Table 45. Japan Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 46. Japan Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 47. India Panic Disorders, by Type USD Million (2015-2020)
  • Table 48. India Panic Disorders, by Application USD Million (2015-2020)
  • Table 49. India Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 50. India Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 51. South Korea Panic Disorders, by Type USD Million (2015-2020)
  • Table 52. South Korea Panic Disorders, by Application USD Million (2015-2020)
  • Table 53. South Korea Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 54. South Korea Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 55. Taiwan Panic Disorders, by Type USD Million (2015-2020)
  • Table 56. Taiwan Panic Disorders, by Application USD Million (2015-2020)
  • Table 57. Taiwan Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 58. Taiwan Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 59. Australia Panic Disorders, by Type USD Million (2015-2020)
  • Table 60. Australia Panic Disorders, by Application USD Million (2015-2020)
  • Table 61. Australia Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 62. Australia Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Panic Disorders, by Type USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Panic Disorders, by Application USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 67. Europe Panic Disorders, by Country USD Million (2015-2020)
  • Table 68. Europe Panic Disorders, by Type USD Million (2015-2020)
  • Table 69. Europe Panic Disorders, by Application USD Million (2015-2020)
  • Table 70. Europe Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 71. Europe Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 72. Germany Panic Disorders, by Type USD Million (2015-2020)
  • Table 73. Germany Panic Disorders, by Application USD Million (2015-2020)
  • Table 74. Germany Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 75. Germany Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 76. France Panic Disorders, by Type USD Million (2015-2020)
  • Table 77. France Panic Disorders, by Application USD Million (2015-2020)
  • Table 78. France Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 79. France Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 80. Italy Panic Disorders, by Type USD Million (2015-2020)
  • Table 81. Italy Panic Disorders, by Application USD Million (2015-2020)
  • Table 82. Italy Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 83. Italy Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 84. United Kingdom Panic Disorders, by Type USD Million (2015-2020)
  • Table 85. United Kingdom Panic Disorders, by Application USD Million (2015-2020)
  • Table 86. United Kingdom Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 87. United Kingdom Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 88. Netherlands Panic Disorders, by Type USD Million (2015-2020)
  • Table 89. Netherlands Panic Disorders, by Application USD Million (2015-2020)
  • Table 90. Netherlands Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 91. Netherlands Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 92. Rest of Europe Panic Disorders, by Type USD Million (2015-2020)
  • Table 93. Rest of Europe Panic Disorders, by Application USD Million (2015-2020)
  • Table 94. Rest of Europe Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 95. Rest of Europe Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 96. MEA Panic Disorders, by Country USD Million (2015-2020)
  • Table 97. MEA Panic Disorders, by Type USD Million (2015-2020)
  • Table 98. MEA Panic Disorders, by Application USD Million (2015-2020)
  • Table 99. MEA Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 100. MEA Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 101. Middle East Panic Disorders, by Type USD Million (2015-2020)
  • Table 102. Middle East Panic Disorders, by Application USD Million (2015-2020)
  • Table 103. Middle East Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 104. Middle East Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 105. Africa Panic Disorders, by Type USD Million (2015-2020)
  • Table 106. Africa Panic Disorders, by Application USD Million (2015-2020)
  • Table 107. Africa Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 108. Africa Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 109. North America Panic Disorders, by Country USD Million (2015-2020)
  • Table 110. North America Panic Disorders, by Type USD Million (2015-2020)
  • Table 111. North America Panic Disorders, by Application USD Million (2015-2020)
  • Table 112. North America Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 113. North America Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 114. United States Panic Disorders, by Type USD Million (2015-2020)
  • Table 115. United States Panic Disorders, by Application USD Million (2015-2020)
  • Table 116. United States Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 117. United States Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 118. Canada Panic Disorders, by Type USD Million (2015-2020)
  • Table 119. Canada Panic Disorders, by Application USD Million (2015-2020)
  • Table 120. Canada Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 121. Canada Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 122. Mexico Panic Disorders, by Type USD Million (2015-2020)
  • Table 123. Mexico Panic Disorders, by Application USD Million (2015-2020)
  • Table 124. Mexico Panic Disorders, by Drug Type USD Million (2015-2020)
  • Table 125. Mexico Panic Disorders, by Sales Channel USD Million (2015-2020)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Panic Disorders: by Type(USD Million)
  • Table 137. Panic Disorders Anxiety Disorders , by Region USD Million (2021-2026)
  • Table 138. Panic Disorders Generalized Anxiety Disorder , by Region USD Million (2021-2026)
  • Table 139. Panic Disorders Obsessive-Compulsive Disorder , by Region USD Million (2021-2026)
  • Table 140. Panic Disorders: by Application(USD Million)
  • Table 141. Panic Disorders Hospitals , by Region USD Million (2021-2026)
  • Table 142. Panic Disorders Specialty Clinics , by Region USD Million (2021-2026)
  • Table 143. Panic Disorders Home Care , by Region USD Million (2021-2026)
  • Table 144. Panic Disorders Others , by Region USD Million (2021-2026)
  • Table 145. Panic Disorders: by Drug Type(USD Million)
  • Table 146. Panic Disorders Anti-Depressants , by Region USD Million (2021-2026)
  • Table 147. Panic Disorders Benzodiazepines , by Region USD Million (2021-2026)
  • Table 148. Panic Disorders: by Sales Channel(USD Million)
  • Table 149. Panic Disorders Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 150. Panic Disorders Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 151. Panic Disorders Online Pharmacy , by Region USD Million (2021-2026)
  • Table 152. South America Panic Disorders, by Country USD Million (2021-2026)
  • Table 153. South America Panic Disorders, by Type USD Million (2021-2026)
  • Table 154. South America Panic Disorders, by Application USD Million (2021-2026)
  • Table 155. South America Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 156. South America Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 157. Brazil Panic Disorders, by Type USD Million (2021-2026)
  • Table 158. Brazil Panic Disorders, by Application USD Million (2021-2026)
  • Table 159. Brazil Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 160. Brazil Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 161. Argentina Panic Disorders, by Type USD Million (2021-2026)
  • Table 162. Argentina Panic Disorders, by Application USD Million (2021-2026)
  • Table 163. Argentina Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 164. Argentina Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 165. Rest of South America Panic Disorders, by Type USD Million (2021-2026)
  • Table 166. Rest of South America Panic Disorders, by Application USD Million (2021-2026)
  • Table 167. Rest of South America Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 168. Rest of South America Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 169. Asia Pacific Panic Disorders, by Country USD Million (2021-2026)
  • Table 170. Asia Pacific Panic Disorders, by Type USD Million (2021-2026)
  • Table 171. Asia Pacific Panic Disorders, by Application USD Million (2021-2026)
  • Table 172. Asia Pacific Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 173. Asia Pacific Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 174. China Panic Disorders, by Type USD Million (2021-2026)
  • Table 175. China Panic Disorders, by Application USD Million (2021-2026)
  • Table 176. China Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 177. China Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 178. Japan Panic Disorders, by Type USD Million (2021-2026)
  • Table 179. Japan Panic Disorders, by Application USD Million (2021-2026)
  • Table 180. Japan Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 181. Japan Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 182. India Panic Disorders, by Type USD Million (2021-2026)
  • Table 183. India Panic Disorders, by Application USD Million (2021-2026)
  • Table 184. India Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 185. India Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 186. South Korea Panic Disorders, by Type USD Million (2021-2026)
  • Table 187. South Korea Panic Disorders, by Application USD Million (2021-2026)
  • Table 188. South Korea Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 189. South Korea Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 190. Taiwan Panic Disorders, by Type USD Million (2021-2026)
  • Table 191. Taiwan Panic Disorders, by Application USD Million (2021-2026)
  • Table 192. Taiwan Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 193. Taiwan Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 194. Australia Panic Disorders, by Type USD Million (2021-2026)
  • Table 195. Australia Panic Disorders, by Application USD Million (2021-2026)
  • Table 196. Australia Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 197. Australia Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Panic Disorders, by Type USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific Panic Disorders, by Application USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 202. Europe Panic Disorders, by Country USD Million (2021-2026)
  • Table 203. Europe Panic Disorders, by Type USD Million (2021-2026)
  • Table 204. Europe Panic Disorders, by Application USD Million (2021-2026)
  • Table 205. Europe Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 206. Europe Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 207. Germany Panic Disorders, by Type USD Million (2021-2026)
  • Table 208. Germany Panic Disorders, by Application USD Million (2021-2026)
  • Table 209. Germany Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 210. Germany Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 211. France Panic Disorders, by Type USD Million (2021-2026)
  • Table 212. France Panic Disorders, by Application USD Million (2021-2026)
  • Table 213. France Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 214. France Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 215. Italy Panic Disorders, by Type USD Million (2021-2026)
  • Table 216. Italy Panic Disorders, by Application USD Million (2021-2026)
  • Table 217. Italy Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 218. Italy Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 219. United Kingdom Panic Disorders, by Type USD Million (2021-2026)
  • Table 220. United Kingdom Panic Disorders, by Application USD Million (2021-2026)
  • Table 221. United Kingdom Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 222. United Kingdom Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 223. Netherlands Panic Disorders, by Type USD Million (2021-2026)
  • Table 224. Netherlands Panic Disorders, by Application USD Million (2021-2026)
  • Table 225. Netherlands Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 226. Netherlands Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 227. Rest of Europe Panic Disorders, by Type USD Million (2021-2026)
  • Table 228. Rest of Europe Panic Disorders, by Application USD Million (2021-2026)
  • Table 229. Rest of Europe Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 230. Rest of Europe Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 231. MEA Panic Disorders, by Country USD Million (2021-2026)
  • Table 232. MEA Panic Disorders, by Type USD Million (2021-2026)
  • Table 233. MEA Panic Disorders, by Application USD Million (2021-2026)
  • Table 234. MEA Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 235. MEA Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 236. Middle East Panic Disorders, by Type USD Million (2021-2026)
  • Table 237. Middle East Panic Disorders, by Application USD Million (2021-2026)
  • Table 238. Middle East Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 239. Middle East Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 240. Africa Panic Disorders, by Type USD Million (2021-2026)
  • Table 241. Africa Panic Disorders, by Application USD Million (2021-2026)
  • Table 242. Africa Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 243. Africa Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 244. North America Panic Disorders, by Country USD Million (2021-2026)
  • Table 245. North America Panic Disorders, by Type USD Million (2021-2026)
  • Table 246. North America Panic Disorders, by Application USD Million (2021-2026)
  • Table 247. North America Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 248. North America Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 249. United States Panic Disorders, by Type USD Million (2021-2026)
  • Table 250. United States Panic Disorders, by Application USD Million (2021-2026)
  • Table 251. United States Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 252. United States Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 253. Canada Panic Disorders, by Type USD Million (2021-2026)
  • Table 254. Canada Panic Disorders, by Application USD Million (2021-2026)
  • Table 255. Canada Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 256. Canada Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 257. Mexico Panic Disorders, by Type USD Million (2021-2026)
  • Table 258. Mexico Panic Disorders, by Application USD Million (2021-2026)
  • Table 259. Mexico Panic Disorders, by Drug Type USD Million (2021-2026)
  • Table 260. Mexico Panic Disorders, by Sales Channel USD Million (2021-2026)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Panic Disorders: by Type USD Million (2015-2020)
  • Figure 5. Global Panic Disorders: by Application USD Million (2015-2020)
  • Figure 6. Global Panic Disorders: by Drug Type USD Million (2015-2020)
  • Figure 7. Global Panic Disorders: by Sales Channel USD Million (2015-2020)
  • Figure 8. South America Panic Disorders Share (%), by Country
  • Figure 9. Asia Pacific Panic Disorders Share (%), by Country
  • Figure 10. Europe Panic Disorders Share (%), by Country
  • Figure 11. MEA Panic Disorders Share (%), by Country
  • Figure 12. North America Panic Disorders Share (%), by Country
  • Figure 13. Global Panic Disorders share by Players 2020 (%)
  • Figure 14. Global Panic Disorders share by Players (Top 3) 2020(%)
  • Figure 15. Global Panic Disorders share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Teva Pharmaceutical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Teva Pharmaceutical Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Sun Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 20. Sun Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 21. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 22. Mylan (United States) Revenue: by Geography 2020
  • Figure 23. Astrazeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. Astrazeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 27. Noven Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Noven Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Recordati Rare Diseases (United States) Revenue, Net Income and Gross profit
  • Figure 30. Recordati Rare Diseases (United States) Revenue: by Geography 2020
  • Figure 31. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2020
  • Figure 33. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 35. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 36. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 37. Global Panic Disorders: by Type USD Million (2021-2026)
  • Figure 38. Global Panic Disorders: by Application USD Million (2021-2026)
  • Figure 39. Global Panic Disorders: by Drug Type USD Million (2021-2026)
  • Figure 40. Global Panic Disorders: by Sales Channel USD Million (2021-2026)
  • Figure 41. South America Panic Disorders Share (%), by Country
  • Figure 42. Asia Pacific Panic Disorders Share (%), by Country
  • Figure 43. Europe Panic Disorders Share (%), by Country
  • Figure 44. MEA Panic Disorders Share (%), by Country
  • Figure 45. North America Panic Disorders Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Teva Pharmaceutical Inc. (United States)
  • Sun Pharmaceuticals (India)
  • Mylan (United States)
  • Astrazeneca (United Kingdom)
  • Abbott Laboratories (United States)
  • Noven Pharmaceuticals, Inc. (United States)
  • Recordati Rare Diseases (United States)
  • F. Hoffmann-La Roche (Switzerland)
  • Eli Lilly and Company (United States)
  • Bristol-Myers Squibb (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation